Welcome to our dedicated page for Nascent Biotech news (Ticker: NBIO), a resource for investors and traders seeking the latest updates and insights on Nascent Biotech stock.
Nascent Biotech, Inc. (NBIO) generates news primarily through developments in its clinical programs, collaborations, and corporate updates related to its lead monoclonal antibody candidate, Pritumumab (PTB). As a clinical-stage biotechnology company focused on cancer therapeutics, many of its announcements center on progress in brain cancer research, particularly glioblastoma, and on regulatory and scientific milestones.
News coverage for NBIO often highlights key clinical events, such as completion and presentation of Phase I trial data, FDA clearance to begin Phase II clinical trials for brain cancer, and updates on Phase II planning and study design. The company also issues press releases when it presents data at major scientific meetings, including poster presentations that summarize safety findings and early signs of biological activity.
Another important category of Nascent Biotech news involves strategic collaborations. The company has announced a research collaboration with Manhattan BioSolutions to explore antibody-drug conjugates using Pritumumab as the targeting antibody, and a collaboration with HypoSpray Pharma to investigate alternative transdermal and transmucosal delivery approaches for PTB. These stories provide insight into how Nascent aims to expand PTB’s potential applications and delivery options.
Investors following NBIO will also see corporate and capital-structure updates, such as the company’s disclosure that it fully repaid a variable convertible note to remove related dilution risk, and its later notice about a filing delinquency that led to quotation on the OTC Markets’ Expert Market. Together, these news items offer a view into both the scientific and financial aspects of Nascent Biotech’s development. This page aggregates such releases so readers can track clinical progress, partnership activity, regulatory milestones, and trading-status updates over time.
Nascent Biotech (OTCQB:NBIO) closed a $740,000 private placement to advance its clinical trials for brain cancer treatments. The funds will facilitate the removal of a partial clinical trial hold imposed by the FDA, allowing the company to initiate Phase I trials for its lead monoclonal antibody, Pritumumab (PTB). CEO Sean Carrick highlighted the strategic choice of equity funding over debt financing, reflecting strong investor interest. Nascent is developing treatments for various cancers and viral infections, including COVID-19.
Nascent Biotech, Inc. (OTCQB:NBIO) announced a significant reduction in liabilities, converting $1.6 million in debt to equity and paying off over $200,000 in liabilities. CFO Lowell Holden highlighted that this debt reduction could enhance investments in upcoming clinical trials for brain cancer. CEO Sean Carrick expressed confidence that the decreased debt will boost shareholder confidence and positively impact the market as the company continues to monetize its assets. The firm is advancing its lead candidate, Pritumumab, for brain cancer trials later this year.